Patents by Inventor Lior Carmon
Lior Carmon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220111030Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I—restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: September 30, 2021Publication date: April 14, 2022Inventor: Lior CARMON
-
Publication number: 20220072113Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: ApplicationFiled: November 21, 2021Publication date: March 10, 2022Inventor: Lior CARMON
-
Patent number: 11179452Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: GrantFiled: November 7, 2016Date of Patent: November 23, 2021Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Patent number: 11135277Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: July 11, 2019Date of Patent: October 5, 2021Assignees: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20200061178Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: July 11, 2019Publication date: February 27, 2020Inventor: Lior CARMON
-
Publication number: 20200062842Abstract: The invention concerns methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti SP antibodies are capable of detecting cell surface expression of these SP domains and therefore they can be used in methods of diagnosis and/or therapy. In one aspect, the invention provides a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. The invention is specifically exemplified with antibodies directed against the signal peptide of MUC1 which is expressed on the surface of various cancer cells, and with signal peptide domains of Mycobacterium tuberculosis. In other aspects the invention provides methods for diagnosis of disease based on the detection of endogenously produced anti SP antibodies.Type: ApplicationFiled: November 14, 2019Publication date: February 27, 2020Inventors: Lior CARMON, Riva KOVJAZIN
-
Publication number: 20190216912Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: March 31, 2019Publication date: July 18, 2019Inventor: Lior CARMON
-
Patent number: 10350284Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: March 31, 2019Date of Patent: July 16, 2019Assignees: Lior Carmon, VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20190185558Abstract: The invention concerns methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti SP antibodies are capable of detecting cell surface expression of these SP domains and therefore they can be used in methods of diagnosis and/or therapy. In one aspect, the invention provides a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. The invention is specifically exemplified with antibodies directed against the signal peptide of MUC1 which is expressed on the surface of various cancer cells, and with signal peptide domains of Mycobacterium tuberculosis. In other aspects the invention provides methods for diagnosis of disease based on the detection of endogenously produced anti SP antibodies.Type: ApplicationFiled: August 14, 2017Publication date: June 20, 2019Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva KOVJAZIN
-
Patent number: 10245309Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: May 8, 2017Date of Patent: April 2, 2019Assignees: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20170354728Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: May 8, 2017Publication date: December 14, 2017Inventor: Lior CARMON
-
Patent number: 9732153Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.Type: GrantFiled: September 13, 2012Date of Patent: August 15, 2017Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva Kovjazin
-
Patent number: 9642903Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: July 15, 2010Date of Patent: May 9, 2017Assignees: LIOR CARMON, VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20170072036Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: ApplicationFiled: November 7, 2016Publication date: March 16, 2017Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior CARMON
-
Patent number: 9487574Abstract: The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: GrantFiled: September 23, 2007Date of Patent: November 8, 2016Assignee: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20140220028Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.Type: ApplicationFiled: September 13, 2012Publication date: August 7, 2014Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventors: Lior Carmon, Riva Kovjazin
-
Publication number: 20120196920Abstract: The present invention relates to novel uses of antisense oligolucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides targeted to AChE mRNA for treating inflammatory disease of the gastroinstestinal tract including inflammatory bowel disease.Type: ApplicationFiled: November 29, 2011Publication date: August 2, 2012Applicant: AMARIN PHARMA, INC.Inventors: Eli Hazum, Lior Carmon
-
Publication number: 20120177677Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Patent number: 7906620Abstract: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.Type: GrantFiled: July 28, 2003Date of Patent: March 15, 2011Assignee: Yeda Research and Development Co. Ltd.Inventors: Lea Eisenbach, Boaz Tirosh, Lior Carmon, Arthur Machlenkin, Adrian Paz, Esther Tzehoval, Matityahu Fridkin
-
Publication number: 20100074925Abstract: The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.Type: ApplicationFiled: September 23, 2007Publication date: March 25, 2010Applicant: VAXIL BIOTHERAPEUTICS LTDInventor: Lior Carmon